Completed PHASE2 INTERVENTIONAL 1-arm NCT00636909

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders (MINI HEME)

Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders

Sponsor: Amgen

Conditions ALL AML APLASTIC ANEMIA CLL CML Chronic Phase, Accelerated Phase, or Blast Crisis MDS MULTIPLE MYELOMA MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA

Interventions Cyclophosphamide G-CSF cyclosporine fludarabine methotrexate

Updated 5 times since 2017 Last updated: Apr 5, 2017 Started: Jul 31, 1999 Primary completion: Mar 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates ALL and AML and is currently completed. Amgen leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Beth Israel Deaconess Medical Center

Data source: Beth Israel Deaconess Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.